Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | TEAD1 | P28347 | 4/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 7/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2820968 | 0.74 | HCAR3 (0.31) | — | |
| SCHEMBL20454191 | 0.70 | HCAR3 (0.49) | CES2CES1PTGDR2PDE2AKMT2A | |
| SCHEMBL4947676 | 0.69 | FLT1 (0.43) | KMT2A | |
| SCHEMBL2055563 | 0.69 | EPHX1 (0.53) | CES2CES1GSK3BPDE2AAKR1C3 | |
| SCHEMBL19024394 | 0.69 | EPHX1 (0.53) | CES2CES1GSK3BPDE2AAKR1C3 | |
| SCHEMBL11483545 | 0.68 | CES2 (0.46) | CES2CES1GSK3BTEAD1PTGDR2 | |
| SCHEMBL2971482 | 0.67 | TRPA1 (0.34) | — | |
| SCHEMBL28275205 | 0.67 | CES2 (0.44) | CES2CES1GSK3BTEAD1PTGDR2 | |
| SCHEMBL11315116 | 0.67 | CES2 (0.46) | CES2CES1GSK3BPDE2AAKR1C3 | |
| SCHEMBL29092145 | 0.66 | PDE2A (0.44) | PTGDR2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940802-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Pfizer Products Inc. (US) | 2008-07-09 | — | — | EP | claimed |
| WO-2007034326-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | claimed |
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC | 2007-03-22 | — | — | US | claimed |
| US-7781435-B2 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100184737-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PFIZER INC (US) | 2010-07-22 | — | — | US | disclosed |
| EP-1940802-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Pfizer Products Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007034326-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | APP, PSEN1, BACE1 | CES2 2226/4885CES1 1847/4885GSK3B 1171/4885 |
| US-20100184737-A1 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | APP, PSEN1, BACE1 | CES2 2226/4885CES1 1847/4885GSK3B 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.